Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 21Leukemia, Lymphocytic, Chronic, B-Cell 14Leukemia 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Hematologic Neoplasms 10Recurrence 8Myelodysplastic Syndromes 8Lymphoma, Non-Hodgkin 4Multiple Myeloma 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Hematologic Diseases 3Philadelphia Chromosome 2Neoplasms 2Myeloproliferative Disorders 2Mastocytosis, Systemic 2Lymphoproliferative Disorders 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Leukemia, Mast-Cell 2Leukemia, Hairy Cell 2Leukemia, Biphenotypic, Acute 2Glioma 2Burkitt Lymphoma 2Bronchiolitis Obliterans Syndrome 2Bone Marrow Diseases 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Waldenstrom Macroglobulinemia 1

Interventions

tagraxofusp 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Blastic Plasmacytoid Dendritic Cell Neoplasm × Other hematologic neoplasm × Clear all
NCT03386513 2024-12-16

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

AbbVie

Phase 1/2 Active not recruiting
179 enrolled 1 FDA
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Disorders, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02113982 2024-08-01

Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

Stemline Therapeutics, Inc.

Phase 1/2 Completed
138 enrolled 23 charts 2 FDA
MyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡